Sava Infond d.o.o. Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Sava Infond d.o.o. grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 15.9% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 800 shares of the biopharmaceutical company’s stock after purchasing an additional 110 shares during the quarter. Sava Infond d.o.o.’s holdings in Regeneron Pharmaceuticals were worth $507,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Brighton Jones LLC boosted its holdings in Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after acquiring an additional 686 shares during the period. Atria Wealth Solutions Inc. lifted its position in shares of Regeneron Pharmaceuticals by 5.7% during the fourth quarter. Atria Wealth Solutions Inc. now owns 1,734 shares of the biopharmaceutical company’s stock worth $1,235,000 after purchasing an additional 93 shares in the last quarter. Sigma Planning Corp boosted its stake in shares of Regeneron Pharmaceuticals by 91.2% in the fourth quarter. Sigma Planning Corp now owns 782 shares of the biopharmaceutical company’s stock valued at $557,000 after purchasing an additional 373 shares during the period. Forvis Mazars Wealth Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals by 1.3% in the fourth quarter. Forvis Mazars Wealth Advisors LLC now owns 3,255 shares of the biopharmaceutical company’s stock valued at $2,319,000 after purchasing an additional 41 shares during the period. Finally, Y Intercept Hong Kong Ltd boosted its stake in shares of Regeneron Pharmaceuticals by 22.3% in the fourth quarter. Y Intercept Hong Kong Ltd now owns 11,525 shares of the biopharmaceutical company’s stock valued at $8,210,000 after purchasing an additional 2,100 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on REGN. Cantor Fitzgerald initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $695.00 price target on the stock. Truist Financial dropped their target price on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating on the stock in a research report on Wednesday, April 30th. Robert W. Baird cut their price target on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating on the stock in a research note on Friday, April 25th. Wall Street Zen downgraded Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 1st. Finally, Canaccord Genuity Group upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, April 22nd. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $836.48.

Regeneron Pharmaceuticals Trading Up 0.4%

NASDAQ REGN opened at $511.92 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20. The company has a 50-day simple moving average of $557.15 and a 200-day simple moving average of $638.15. The firm has a market capitalization of $55.27 billion, a PE ratio of 13.03, a price-to-earnings-growth ratio of 1.87 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The company had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The business’s revenue was down 3.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $9.55 earnings per share. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.69%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.